MonaLEESA: A Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer who Received No Prior Therapy for Advanced Disease (MonoLESSA)
Aims: The purpose of the study is to find out if the drug LEE011, when taken with the standard treatment (letrozole), helps to reduce the growth of breast cancer cells in postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer. Since the researchers do not know if combining LEE011 and letrozole is better than letrozole alone, the comparison needs to be done to learn which of the two treatments (letrozole plus LEE011 or letrozole plus placebo) gives better results.
Diagnosis: Postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH14-008
Sponsor: MonaLEESA
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes 

LATTE: Long Term Anastrozole versus Tamoxifen Treatment Effects
Aims: The LATTE study is an extension study to the now closed ATAC trial that took place 10 years ago. LATTE aims to collect long term follow-up information since the conclusion of the ATAC study and for at least another 5 years.
Diagnosis: Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH13-352
Sponsor: American Cancer Society, Inc/ Queen Mary University of London
Contact: Interested patients should contact research coordinator Nancy Haefling at 847.503.1188
Open to Enrollment: Yes 

UC13-1-000 Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Presistent Epithelial Ovarian Cancer
Aims: The purpse of this study is to find the safest dose of mifepristone when given with standard chemotherapy using carboplatin and gemcitabine. The study will look at the side effects, how your body processes the drugs, and the effects of the drug combination on your body and your cancer.
Diagnosis: Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH14-248
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

A011106 ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
Aims: The purpse of this study is to determine whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole when given before surgery to shrink the cancer and stop it from growing. Anastrozole inhibits tumor growth by reducing the levels of estrogen and has been approved by the Food and Drug Administration (FDA) of the United States for use after surgery for postmenopausal women with estrogen receptor positive breast cancer.
Diagnosis: Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH14-308
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

× Alternate Text